Harmony Biosciences upgraded by Jefferies with a new price target
$HRMY
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies upgraded Harmony Biosciences from Hold to Buy and set a new price target of $61.00 from $57.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/10/2024 | Outperform | Raymond James | |
| 9/10/2024 | $56.00 | Buy | UBS |
| 6/21/2024 | $48.00 | Buy | Citigroup |
| 1/2/2024 | $30.00 | Neutral → Underperform | BofA Securities |
| 9/25/2023 | $40.00 → $31.00 | Neutral → Sell | Goldman |
| 9/7/2023 | $59.00 | Buy | Berenberg |
| 4/20/2023 | $35.00 | Neutral | BofA Securities |
| 10/14/2022 | $57.00 → $61.00 | Hold → Buy | Jefferies |
Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $52 price target.
Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $52 price target.
WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years On Track to Submit sNDA for Pitolisant in Idiopathic Hypersomnia (IH) in Q4 2024 Based on Updated Strong and Sustained Efficacy Data from Long-Term Extension Study Next-Gen Pitolisant-GR and Pitolisant-HD Programs Advance; IND for Potential Best-In-Class, Novel Orexin-2 Agonist On Track for mid-2025, Extending Leadership in Sleep/Wake Beyond 2040s Highlights Most Advanced Development Program and Proven Serotonergic (5-HT2) Mechanism of Action For EPX-100 in Rare Epilepsies; Pivotal Phase 3 Trial in Dravet Syndrome Ongoing; Phase 3 Registrational Trial in
PLYMOUTH MEETING, Pa., Oct. 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report third quarter 2024 financial results on Tuesday, October 29, 2024, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on October 29, 2024, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial (800) 245-3047 (domestic) or (203) 518-9765 (international), and reference passcode HRMYQ324. It is recommended that you dial in at least 10 minutes prior to the call. The live and r
WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program Advances Based on Pilot Pharmacokinetic (PK) Data with PDUFA Date Expected in 2028 to Extend Pitolisant Franchise Beyond 2040 WAKIX Patent Upheld Again - U.S. Patent and Trademark Office (USPTO) Issues Final Denial After Two Attempts to Challenge the WAKIX Patent Received U.S. Food and Drug Administration (FDA) Approval and Launched WAKIX for the Treatment of EDS in Pediatric Patients with Narcolepsy Providing the First and Only Non-Scheduled Treatment Option On Track to Submit Supplemental New Drug Application for Pitolisant in Idiopa
Raymond James resumed coverage of Harmony Biosciences with a rating of Outperform
UBS initiated coverage of Harmony Biosciences with a rating of Buy and set a new price target of $56.00
Citigroup initiated coverage of Harmony Biosciences with a rating of Buy and set a new price target of $48.00
SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
424B7 - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
424B7 - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
PLYMOUTH MEETING, Pa., Jan. 6, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that John C. Jacobs is stepping down as President and Chief Executive Officer and a member of the Board of Directors to pursue another opportunity. The Harmony Board of Directors has named Jeffrey M. Dayno, MD, Harmony's Executive Vice President and Chief Medical Officer, as interim CEO effective immediately. Jeff Aronin, Harmony's founder and Board chairman, will continue to lead the Board of Directors as well as
PLYMOUTH MEETING, Pa., Nov. 22, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the appointment of Linda Szyper to the Company's Board of Directors. Ms. Szyper brings extensive healthcare and pharmaceutical knowledge with expertise anchored in more than 30 years of experience that spans both pharmaceutical sales and marketing as well as healthcare communications services. Mos
PLYMOUTH MEETING, Pa., May 18, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the appointment of John C. Jacobs, President and CEO of Harmony, to the Life Sciences Pennsylvania's (LSPA) Board of Directors, effective May 6, 2021. John Jacobs' election to the board is accompanied by other leaders representing the breadth, diversity and geographic reach of LS
PLYMOUTH MEETING, Pa., Nov. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences: Citi's 2024 Global Healthcare Conference Location: MiamiTuesday, December 3, 2024Piper Sandler 36th Annual Healthcare Conference Location: New York CityFireside Chat: Wednesday, December 4, 2024, at 8:30 a.m., ETA webcast of the fireside chat will be available on the investor page of Harmony's website at https://ir.harmonybiosciences.com/. About Harmony BiosciencesH
PLYMOUTH MEETING, Pa., Oct. 30, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) (the "Company") today announced the pricing of the previously announced underwritten public offering of an aggregate of 8,000,000 shares of the Company's common stock, par value $0.00001 per share ("Common Stock"), by Marshman Fund Trust II and Valor IV Pharma Holdings, LLC (together, the "Selling Shareholders") at a public offering price of $31.00 per share. The Selling Shareholders have granted the underwriter a 30-day option to purchase an additional 1,200,000 shares of Common Stock from the Selling Shareholders at the public offering price, less underwriting discounts and commissions. Th
-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent
4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)